A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders

Steven J. Frucht, Yvette Bordelon, William H. Houghton, Dayton Reardan

Research output: Contribution to journalArticlepeer-review

71 Scopus citations

Abstract

Sodium oxybate is currently approved in the United States exclusively for the treatment of cataplexy in narcoleptic patients. In a prior article published in this journal, we reported a patient with severe posthypoxic myoclonus whose myoclonus improved with ethanol and also with treatment with sodium oxybate. We extend this preliminary observation to five other patients with ethanol-responsive movement disorders in an open-label, dose-titration, add-on, 8-week trial. All five patients (one with severe alcohol-responsive posthypoxic myoclonus, two with ε-sarcoglycan-linked myoclonus-dystonia, and two with essential tremor) experienced improvement from baseline of 50% or greater as measured by blinded videotape review. Tolerability was satisfactory, with dose-dependent sedation as the most common side effect. Further studies of this drug in hyperkinetic movement disorders are warranted.

Original languageEnglish
Pages (from-to)1330-1337
Number of pages8
JournalMovement Disorders
Volume20
Issue number10
DOIs
StatePublished - Oct 2005
Externally publishedYes

Keywords

  • Ethanol
  • Myoclonus
  • Sodium oxybate
  • Tremor
  • Xyrem
  • γ-hydroxybutyric acid

Fingerprint

Dive into the research topics of 'A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders'. Together they form a unique fingerprint.

Cite this